Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Synairgen (SNG)

Price 7.02p on 23-04-2024 at 16:30:04
Change 0.27p 4%
Buy 7.38p
Sell 6.66p
Buy / Sell SNG Shares
Last Trade: Sell 3,900.00 at 6.876p
Day's Volume: 30,505
Last Close: 7.02p
Open: 6.75p
ISIN: GB00B0381Z20
Day's Range 0.00p - 0.00p
52wk Range: 4.20p - 13.00p
Market Capitalisation: £14m
VWAP: 6.717327p
Shares in Issue: 201m

Recent Trades History Synairgen (SNG)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 3,900 6.876p Ordinary
13:57:59 - 23-Apr-24
Sell* 390 6.876p Ordinary
13:52:00 - 23-Apr-24
Sell* 299 6.876p Ordinary
13:40:29 - 23-Apr-24
Sell* 3,017 6.8976p Ordinary
13:22:04 - 23-Apr-24
Sell* 635 6.8976p Ordinary
11:12:30 - 23-Apr-24
Sell* 1,000 6.696p Ordinary
09:34:20 - 23-Apr-24
Sell* 1,025 6.605p Ordinary
08:44:01 - 23-Apr-24
Sell* 9,820 6.615p Ordinary
08:24:58 - 23-Apr-24
Sell* 10,000 6.665p Ordinary
08:20:47 - 23-Apr-24
Buy* 319 7.35p Ordinary
08:00:50 - 23-Apr-24

Share Price History for Synairgen

Time period:
to
Date Open High Low Close Volume

Share News for Synairgen

IN BRIEF: Synairgen names Phytome's Joseph Colliver as CFO

11th Oct 2023 11:19

Synairgen PLC - Southampton, England-based drug discovery and biotechnology firm developing SNG001 antiviral treatment for lung infections - Appoints Joseph Colliver as chief financial officer with effect from November 6. Current CFO John Ward will step down from his role on November 3. Colliver has previously held CFO and senior commercial roles at Sativa Group Inc, and within the Kantar division of WPP PLC. He is currently CFO at Phytome Life Sciences Ltd, a pharmaceutical manufacturing firm focused on plant-based medicines. Read More

Synairgen promotes Marcin Mankowski to chief medical officer

3rd Oct 2023 09:59

(Alliance News) - Synairgen PLC on Tuesday promoted Marcin Mankowski to chief medical officer, effective immediately. Read More

IN BRIEF: Synairgen narrows interim loss on reduced R&D spending

21st Sep 2023 13:48

Synairgen PLC - Southampton, England-based drug discovery and biotechnology firm developing SNG001 antiviral treatment for lung infections - Pretax loss narrows to GBP5.2 million in six months that ended June 30 from GBP14.0 million a year before. Has no revenue either year, but research and development spending is reduced to GBP3.5 million from GBP11.1 million, as phase 3 Sprinter trial of SNG001 is mostly completed in 2022. Since the start of the second half, receives GBP2.4 million R&D tax credit, which adds to GBP14.6 million cash balance on June 30. Read More

UK shareholder meetings calendar - next 7 days

22nd Jun 2023 15:44

Read More

EARNINGS SUMMARY: Synairgen loss narrows; aims to develop SNG001

27th Apr 2023 14:44

(Alliance News) - The following is a round-up of earnings updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

FTSE 100 Latest
Value8,044.81
Change20.94

Login to your account

Forgot Password?

Not Registered